Figure 1.

Survival Curves Illustrating Adjusted Differences in Treatment Length for Buprenorphine-Naloxone by Primary Insurance Payment Source

NOTES: Authors’ analysis of the IMS LifeLink database (N=27,235 individuals initiating first episodes of buprenorphine-naloxone treatment in 2010–2012). Each line represents the regression-adjusted survival curve for individuals with Medicare Part D, Medicaid Fee-for-Service, Third-Party Commercial Insurance, or Cash Payment as their primary source of payment. Models adjust for age, sex, prescriber type, county level variables (county urbanicity, an indicator for crossing county lines for treatment, the primary care physician population ratio, the buprenorphine prescriber to population ratio, median income, non-minority population ratio, and county overdose death rate), and state fixed effects.